The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Open accessAbstract
Based upon knowledge of the hydrolytic profile of major β-lactamases found in Gram-negative bacteria, we tested the efficacy of the combination of ceftazidime-avibactam (CAZ-AVI) with aztreonam (ATM) against carbapenem-resistant enteric bacteria possessing metallo-β-lactamases (MBLs). Disk diffusion and agar-based antimicrobial susceptibility testing were initially performed to determine the in vitro efficacy of a unique combination of CAZ-AVI and ATM against 21 representative Enterobacteriaceae isolates with a complex molecular background that included bla IMP , bla NDM , bla OXA-48 , bla CTX-M , bla AmpC , and combinations thereof. Time-kill assays were conducted, and the in vivo efficacy of this combination was assessed in a murine neutropenic thigh infection model. By disk diffusion assay, all 21 isolates were resistant to CAZ-AVI alone, and 19/21 were resistant to ATM. The in vitro activity of CAZ-AVI in combination with ATM against diverse Enterobacteriaceae possessing MBLs was demonstrated in 17/21 isolates, where the zone of inhibition was ≥21 mm. All isolates demonstrated a reduction in CAZ-AVI agar dilution MICs with the addition of ATM. At 2 h, time-kill assays demonstrated a ≥4-log 10 -CFU decrease for all groups that had CAZ-AVI with ATM (8 μg/ml) added, compared to the group treated with CAZ-AVI alone. In the murine neutropenic thigh infection model, an almost 4-log 10 -CFU reduction was noted at 24 h for CAZ-AVI (32 mg/kg every 8 h [q8h]) plus ATM (32 mg/kg q8h) versus CAZ-AVI (32 mg/kg q8h) alone. The data presented herein require us to carefully consider this new therapeutic combination to treat infections caused by MBL-producing Enterobacteriaceae .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vital signs: carbapenem-resistant Enterobacteriaceae.
(2013) · PubMed Central · Cited by 603
van Duin, D., & Bonomo, R. A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw243 · Cited by 549
Self-citationEpstein, L., Hunter, J. C., Arwady, M. A., Tsai, V., Stein, L., Gribogiannis, M., Frias, M., Guh, A. Y., Laufer, A. S., Black, S., et al. (2014) · JAMA · doi:10.1001/jama.2014.12720 · Cited by 400
New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
Drawz, S. M., Papp-Wallace, K. M., & Bonomo, R. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00826-13 · Cited by 286
Self-citationFirst Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
Humphries, R. M., Yang, S., Hemarajata, P., Ward, K. W., Hindler, J. A., Miller, S. A., & Gregson, A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01165-15 · Cited by 255
Self-citationSpotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections
Falcone, M., & Paterson, D. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw239 · Cited by 180
Self-citationLascols, C., Hackel, M., Marshall, S. H., Hujer, A. M., Bouchillon, S., Badal, R., Hoban, D., & Bonomo, R. A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr240 · Cited by 167
Self-citationCastanheira, M., Mills, J. C., Costello, S. E., Jones, R. N., & Sader, H. S. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00163-15 · Cited by 123
Pagès, J., Peslier, S., Keating, T. A., Lavigne, J., & Nichols, W. W. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01585-15 · Cited by 111
Mojica, M. F., Ouellette, C. P., Leber, A. L., Becknell, B., Ardura, M. I., Pérez, F., Shimamura, M., Bonomo, R. A., Aitken, S. L., & Shelburne, S. A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00264-16 · Cited by 80
Self-citation
Cited by
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Self-citationRodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings
Wu, W., Feng, Y., Tang, G., Qiao, F., McNally, A., & Zong, Z. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-18 · Cited by 700
Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
Sheu, C.-C., Chang, Y.-T., Lin, S.-Y., Chen, Y.-H., & Hsueh, P.-R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00080 · Cited by 520
Falcone, M., Daikos, G. L., Tiseo, G., Bassoulis, D., Giordano, C., Galfo, V., Leonildi, A., Tagliaferri, E., Barnini, S., Sani, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa586 · Cited by 380
Boyd, S. E., Livermore, D. M., Hooper, D. C., & Hope, W. W. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00397-20 · Cited by 315
Wright, H., Bonomo, R. A., & Paterson, D. L. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.09.001 · Cited by 256
Self-citationEscalating antimicrobial resistance among Enterobacteriaceae: Focus on carbapenemases
Lynch, J. P., Clark, N. M., & Zhanel, G. G. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1904891 · Cited by 58
The real crisis in antimicrobial resistance: failure to anticipate and respond
Bonomo, R. A., Perez, F., Hujer, A. M., Hujer, K. M., & Vila, A. J. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciad758 · Cited by 33
“A tetrapeptide insertion in the E. coli PBP3 was found to diminish the impact of aztreonam added to ceftazidime/avi-bactam [21]; higher amounts of aztreo-nam were required to lower minimum inhibitory concentrations (MICs) to the triple combination [20].”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Marshall, S., Hujer, A. M., Rojas, L. J., Papp-Wallace, K. M., Humphries, R. M., Spellberg, B., Hujer, K. M., Marshall, E. K., Rudin, S. D., Perez, F., Wilson, B. M., Wasserman, R. B., Chikowski, L., Paterson, D. L., Vila, A. J., van Duin, D., Kreiswirth, B. N., Chambers, H. F., Fowler, V. G., Jacobs, M. R., Pulse, M. E., Weiss, W. J., & Bonomo, R. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2017-04
- Volume
- 61
- Issue
- 4
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2587434779
- Cited by
- 293
- References
- 13
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.